Synartro

Synartro is a Swedish research and development company focused on creating innovative treatments for osteoarthritis (OA) in both humans and animals. The company utilizes a patented drug delivery platform that combines existing proven medications with advanced delivery technologies to enhance treatment effectiveness. Its lead program, SYN321, features a novel therapy that covalently binds diclofenac to hyaluronan, targeting knee OA, a condition that often leaves many patients without sufficient pain relief. By developing local injection treatments, Synartro aims to provide sustained efficacy while minimizing systemic side effects, ultimately empowering clinicians to better manage and potentially halt the progression of this debilitating disease.